Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia

Wei Mu, Anqi Zhang, Xingcheng Yang, Xiaoxi Zhou, Jie Zhao, Yicheng Zhang, Weiwei Tian, Junjie Shen, Haoyue Qin, Yingzi Zhang, Cheng Qian, Jia Wei

Blood (2025) 146 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2025-1639

Published: 2025

Journal Articles

Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

Juan Peng, Zekai Mao, Yang Cao, Na Wang, Jue Wang, Yang Yang, Jinghuan Xu, Fankai Meng, Liting Chen, Xia Mao, Jiaqi Guo, Xiaoxi Zhou, Yicheng Zhang, Jia Wei

Blood (2025) 146 (Supplement 1): 3712.

https://doi.org/10.1182/blood-2025-3712

Published: 2025

Journal Articles

First-in-human Phase I study of autologous CD5-knockout anti-CD5 CAR-T cells in CD5⁺ hematologic malignancies

Jiali Cheng, Li Zhu, Jia Wu, Yuhan Zeng, Xia Mao, Jue Wang, Liang Huang, Yi Xiao, Xiaoxi Zhou, Wei Mu, Xiaojian Zhu

Blood (2025) 146 (Supplement 1): 5949.

https://doi.org/10.1182/blood-2025-5949

Published: 2025

Journal Articles

Survival prediction in relapsed/refractory B-cell lymphoma treated with CAR-T therapy: An AI-optimized cox regression model based on CCL5, scgf-β, and TRAIL

Hu Qian, Zekai Mao, Anqi Zhang, Xiaoying Zhang, Xingcheng Yang, Juan Peng, Jiaqi Guo, Liting Chen, Hui Luo, Li Zhu, Xiaoxi Zhou, Yang Yang, Na Wang, Jue Wang, Yicheng Zhang, Jia Wei

Blood (2025) 146 (Supplement 1): 4115.

https://doi.org/10.1182/blood-2025-4115

Published: 2025

Journal Articles

Enhanced efficacy and safety of optimized tandem CD19/CD20 CAR T-cell Therapy in refractory/relapsed B-cell lymphoma

Jiaqi Guo, Ang Zhang, Weiwei Tian, Xiaoxi Zhou, Xiao Zhao, Yang Cao, Shaolong He, Jie Zhao, Lihong Liu, Lifang Huang, Yicheng Zhang, Bing Liu, Jia Wei

Blood (2025) 146 (Supplement 1): 2325.

https://doi.org/10.1182/blood-2025-2325

Published: 2025

Journal Articles

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

Blood (2025) 146 (Supplement 1): 3689.

https://doi.org/10.1182/blood-2025-3689

Published: 2025

Journal Articles

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Blood (2025) 146 (Supplement 1): 3684.

https://doi.org/10.1182/blood-2025-3684

Published: 2025

Journal Articles

An IL-10-incorporated predictive model for late immune effector cell-associated hematotoxicity following CAR-T therapy in B-cell malignancies

Shujia Zhang, Liang Huang, Hui Luo, Shanwei Ye, Xiaoxi Zhou

Blood (2025) 146 (Supplement 1): 4167.

https://doi.org/10.1182/blood-2025-4167

Published: 2025

Journal Articles

CARMA-1: The phase I Study of SENL101, a naturally selected nanobody based CD7 CAR-T therapy, in relapsed or refractory T-ALL/lbl

Xiangyu Zhao, Wei Li Zhao, Xiaoxi Zhou, Huilai Zhang, Ting Niu, Hongsheng Zhou, Aibin Liang, Xi Zhang, Meng Lv, Lingshuang Sheng, Na Kuang, Xiaojun Huang

Blood (2025) 146 (Supplement 1): 5931.

https://doi.org/10.1182/blood-2025-5931

Published: 2025

Journal Articles

Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Blood (2024) 144 (Supplement 1): 3120.

https://doi.org/10.1182/blood-2024-206700

Published: 2024

Journal Articles

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

Yi Miao, Wenyu Li, Kaiyang Ding, Fei Li, Xiaojing Yan, Xiaoxi Zhou, Caixia Li, Guohui Cui, Liqun Zou, Bing Xiu, Xiangxiang Zhou, Liansheng Zhang, Fuling Zhou, Hongmei Jing, Jianli Wang, Ziheng Guo, Jianyong Li

Blood (2024) 144 (Supplement 1): 6372.

https://doi.org/10.1182/blood-2024-201339

Published: 2024

Journal Articles

A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

Blood (2024) 144 (Supplement 1): 4205.

https://doi.org/10.1182/blood-2024-206408

Published: 2024

Journal Articles

Tandem CD19/20 CAR-T Showed Durable Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma: Interim Results from a Multicenter Phase I/II Trial

Jia Wei, Xiaoxi Zhou, Hui Luo, Yang Cao, Jiaqi Guo, Jie Zhao, Lifang Huang, Ang Zhang, Lihong Liu, Weiwei Tian, Yicheng Zhang

Blood (2024) 144 (Supplement 1): 3132.

https://doi.org/10.1182/blood-2024-205207

Published: 2024

Journal Articles

Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients

Blood (2023) 142 (Supplement 1): 4851.

https://doi.org/10.1182/blood-2023-178624

Published: 2023

Journal Articles

CD19/CD22 CAR T-Cell Therapy Following Autologous Transplantation Is an Optimizing Strategy in Relapsed/Refractory Central Nervous System Lymphoma

Qiuxia Yu, Daizi Gang, Jue Wang, Liang Huang, Chunrui Li, Yicheng Zhang, Xiaoxi Zhou, Yang Cao

Blood (2023) 142 (Supplement 1): 6855.

https://doi.org/10.1182/blood-2023-180363

Published: 2023

Journal Articles

Treatment of Relapsed/Refractory Hgbcl and Bukitt's Lymphoma with c-Myc Rearrangement: A Multi-Center, Open-Label, Phase 2 Study of PC-002 (SepB), a First-in-Class Deubiquitinase Inhibitor Inducing Myc Degradation

Blood (2023) 142 (Supplement 1): 1754.

https://doi.org/10.1182/blood-2023-190995

Published: 2023

Journal Articles

Phase 1 Dose Escalation Study of the Anti-CD7 CAR-T Therapy in Relapsed/Refractory T-Cell Acute Leukemia and Lymphoblastic Lymphoma

Jiali Cheng, Jue Wang, Xia Mao, Wei Mu, Shijia Sun, Xiaoxi Zhou, Liang Huang

Blood (2023) 142 (Supplement 1): 6863.

https://doi.org/10.1182/blood-2023-184370

Published: 2023

Journal Articles

MIP3α As an Early Prognostic Predictor for Patients with B-Cell Malignancies Receiving CD19/CD22-Redirected CAR T-Cell Cocktail Therapy

Jin Jin, Jiali Cheng, Na Wang, Liang Huang, Xiaoxi Zhou, Liting Chen, Hui Luo, Tianjiao Liu, Jiao Meng

Blood (2022) 140 (Supplement 1): 10265–10266.

https://doi.org/10.1182/blood-2022-156710

Published: 2022

Journal Articles

The Safety and Efficacy of p CAR-19B, a Scfv Humanlized CD19-Directed CAR-T for Patients with Relapsed/Refactory (R/R) CD19+ B-ALL

Blood (2022) 140 (Supplement 1): 4625–4626.

https://doi.org/10.1182/blood-2022-162134

Published: 2022

Journal Articles

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Blood (2021) 137 (21): 2890–2901.

https://doi.org/10.1182/blood.2020008936

Published: 2021

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia

Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

First-in-human Phase I study of autologous CD5-knockout anti-CD5 CAR-T cells in CD5⁺ hematologic malignancies

Survival prediction in relapsed/refractory B-cell lymphoma treated with CAR-T therapy: An AI-optimized cox regression model based on CCL5, scgf-β, and TRAIL

Enhanced efficacy and safety of optimized tandem CD19/CD20 CAR T-cell Therapy in refractory/relapsed B-cell lymphoma

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

An IL-10-incorporated predictive model for late immune effector cell-associated hematotoxicity following CAR-T therapy in B-cell malignancies

CARMA-1: The phase I Study of SENL101, a naturally selected nanobody based CD7 CAR-T therapy, in relapsed or refractory T-ALL/lbl

Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

Tandem CD19/20 CAR-T Showed Durable Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma: Interim Results from a Multicenter Phase I/II Trial

Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients

CD19/CD22 CAR T-Cell Therapy Following Autologous Transplantation Is an Optimizing Strategy in Relapsed/Refractory Central Nervous System Lymphoma

Treatment of Relapsed/Refractory Hgbcl and Bukitt's Lymphoma with c-Myc Rearrangement: A Multi-Center, Open-Label, Phase 2 Study of PC-002 (SepB), a First-in-Class Deubiquitinase Inhibitor Inducing Myc Degradation

Phase 1 Dose Escalation Study of the Anti-CD7 CAR-T Therapy in Relapsed/Refractory T-Cell Acute Leukemia and Lymphoblastic Lymphoma

MIP3α As an Early Prognostic Predictor for Patients with B-Cell Malignancies Receiving CD19/CD22-Redirected CAR T-Cell Cocktail Therapy

The Safety and Efficacy of p CAR-19B, a Scfv Humanlized CD19-Directed CAR-T for Patients with Relapsed/Refactory (R/R) CD19+ B-ALL

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only